MXPA04005134A - Novedosas moleculas de auto-montaje. - Google Patents

Novedosas moleculas de auto-montaje.

Info

Publication number
MXPA04005134A
MXPA04005134A MXPA04005134A MXPA04005134A MXPA04005134A MX PA04005134 A MXPA04005134 A MX PA04005134A MX PA04005134 A MXPA04005134 A MX PA04005134A MX PA04005134 A MXPA04005134 A MX PA04005134A MX PA04005134 A MXPA04005134 A MX PA04005134A
Authority
MX
Mexico
Prior art keywords
self
assembly
target
assembly molecules
molecules
Prior art date
Application number
MXPA04005134A
Other languages
English (en)
Inventor
Zhang Jianbing
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of MXPA04005134A publication Critical patent/MXPA04005134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electroluminescent Light Sources (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se proporciona un metodo para formar un complejo multimerico, el cual tenga afinidad para un objetivo. Este metodo comprende>: obtener una pluralidad de moleculas de auto-montaje, dichas moleculas de auto-montaje incluyen unidades de auto-montaje, dichas moleculas de auto-montaje incluyen unidades de auto-montaje complementarias, tal como la subunidad B de la verotoxina, cada una de las cuales se conecta operativamente a un dominio de interaccion, tal como un anticuerpo de dominio de interaccion, tal como un anticuerpo de dominio sencillo, especifico para el objetivo; y combinar dichas moleculas de auto-montaje de modo que al menos tres a dichas moleculas de auto-montaje sean unidas simultaneamente entre si, para permitir asi que los anticuerpos de dominio sencillo se unan a dicho objetivo.
MXPA04005134A 2001-11-30 2002-11-29 Novedosas moleculas de auto-montaje. MXPA04005134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33409801P 2001-11-30 2001-11-30
PCT/CA2002/001829 WO2003046560A2 (en) 2001-11-30 2002-11-29 Self-assembly molecules

Publications (1)

Publication Number Publication Date
MXPA04005134A true MXPA04005134A (es) 2004-08-11

Family

ID=23305560

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005134A MXPA04005134A (es) 2001-11-30 2002-11-29 Novedosas moleculas de auto-montaje.

Country Status (14)

Country Link
US (1) US7655412B2 (es)
EP (1) EP1456651B1 (es)
JP (1) JP4471656B2 (es)
CN (1) CN100335900C (es)
AT (1) ATE394673T1 (es)
AU (1) AU2002349228B2 (es)
BR (1) BR0214621A (es)
CA (1) CA2468583C (es)
DE (1) DE60226486D1 (es)
DK (1) DK1456651T3 (es)
ES (1) ES2306794T3 (es)
MX (1) MXPA04005134A (es)
NZ (1) NZ532838A (es)
WO (1) WO2003046560A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
EP2711025A3 (en) * 2003-06-25 2014-09-10 Massachusetts Institute of Technology Self-assembling peptides incorporating modifications and methods of use thereof
EP2267028A3 (en) * 2003-06-30 2011-07-27 Domantis Limited Dual specific single domain antibodies (dAb) conjugated to PEG
ES2315664T3 (es) * 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
AU2004293502B2 (en) * 2003-11-28 2010-12-02 National Research Council Of Canada Anticarcinoma antibodies and uses thereof
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
JP5269597B2 (ja) * 2005-09-27 2013-08-21 ナショナル リサーチ カウンシル オブ カナダ 血液―脳隔壁エピトープとその利用
EP2121726A4 (en) * 2006-12-04 2010-10-20 Innovative Purification Techno PROTEIN PARTICLE
US8586315B2 (en) * 2007-05-30 2013-11-19 Innovative Purification Technologies Pty Ltd Fluorescent protein particles
EP2692736B1 (en) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
CA2740561C (en) 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
US20110318348A1 (en) * 2008-10-14 2011-12-29 National Research Council Of Canada Induction of mucosal immune responses by mucosal delivery pentabody complex (mdpc)
US20110269148A1 (en) * 2008-11-26 2011-11-03 National Cheng Chung University Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
US20100247529A1 (en) * 2009-03-20 2010-09-30 William Patterson Cooperative and dynamic assembly of affinity complexes
CA2800565C (en) 2010-04-27 2019-06-04 National Research Council Of Canada Anti-icam-1 single domain antibody and uses thereof
CA2813133C (en) 2010-10-01 2023-10-31 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
WO2012055030A1 (en) 2010-10-25 2012-05-03 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
AU2012211011A1 (en) 2011-01-28 2013-08-15 National Research Council Of Canada Engineering of immunoglobulin domains
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
EP2794661B1 (en) 2011-12-20 2019-03-06 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
CN114163530A (zh) 2012-04-20 2022-03-11 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
CN104870472A (zh) 2012-10-24 2015-08-26 加拿大国家研究委员会 抗空肠弯曲杆菌抗体及其用途
MX2016011561A (es) 2014-03-06 2017-04-13 Nat Res Council Canada Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.
EP3114140B1 (en) 2014-03-06 2019-02-27 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
UA120048C2 (uk) 2014-03-06 2019-09-25 Нешнл Рісеч Каунсіл Оф Канада Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)
CN104004093B (zh) * 2014-06-03 2017-01-18 大连理工大学 一种抗人甲状旁腺激素的纳米抗体及其筛选方法和应用
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
EP3204411A4 (en) 2014-10-10 2018-03-28 National Research Council of Canada Anti-tau antibody and uses thereof
US10487153B2 (en) 2015-06-10 2019-11-26 National Research Council Of Canada Carbonic anhydrase IX-specific antibodies and uses thereof
WO2018007950A1 (en) 2016-07-06 2018-01-11 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
WO2018109663A1 (en) 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
WO2018138681A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
AU2018212860A1 (en) 2017-01-30 2019-08-15 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
WO2020086793A1 (en) * 2018-10-25 2020-04-30 Hao Shen Self-assembling protein homo-polymers
CN114099701B (zh) * 2021-11-29 2023-11-10 华中科技大学同济医学院附属协和医院 一种自组装复合多肽及其制备方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
AU3386597A (en) * 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
AU6909298A (en) * 1996-10-28 1998-05-22 Novartis Ag Method for the oligomerisation of peptides
ES2227833T3 (es) * 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
ATE293994T1 (de) * 1997-12-01 2005-05-15 Fang Fang Multivalente rekombinante antikörper zur behandlung von hrv infektionen
US6310043B1 (en) * 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
WO2000044908A2 (en) * 1999-02-01 2000-08-03 Beth Israel Deaconess Medical Center Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
WO2000061183A2 (en) * 1999-04-09 2000-10-19 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
AU7865900A (en) 1999-10-08 2001-04-23 Active Biotech Ab AB5 toxin B subunit mutants with altered chemical conjugation characteristics
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
WO2001053354A2 (en) * 2000-01-20 2001-07-26 Chiron Corporation Methods for treating tumors using a fusion protein comprising il-2- polypeptides and p185-specific binding molecules

Also Published As

Publication number Publication date
CN1596371A (zh) 2005-03-16
DE60226486D1 (de) 2008-06-19
DK1456651T3 (da) 2008-09-01
NZ532838A (en) 2008-05-30
AU2002349228B2 (en) 2007-06-14
US7655412B2 (en) 2010-02-02
AU2002349228A1 (en) 2003-06-10
EP1456651A2 (en) 2004-09-15
BR0214621A (pt) 2004-10-13
CN100335900C (zh) 2007-09-05
JP2005510719A (ja) 2005-04-21
WO2003046560A2 (en) 2003-06-05
ATE394673T1 (de) 2008-05-15
ES2306794T3 (es) 2008-11-16
JP4471656B2 (ja) 2010-06-02
WO2003046560A3 (en) 2003-09-04
US20060051292A1 (en) 2006-03-09
CA2468583C (en) 2012-05-01
CA2468583A1 (en) 2003-06-05
EP1456651B1 (en) 2008-05-07
WO2003046560B1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
MXPA04005134A (es) Novedosas moleculas de auto-montaje.
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
WO2007044616A3 (en) Optimized anti-cd30 antibodies
BRPI0314814C1 (pt) anticorpo compreendendo uma variante de fc
WO2009088805A3 (en) Antibody targeting through a modular recognition domain
AU9399501A (en) Therapeutic antibodies
MA33213B1 (fr) Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
GEP20125398B (en) Human monoclonal antibodies to activin receptor-like kinase-1
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
IL196914A (en) Isolated monoclonal antibodies with sequences of different regions that specifically bind il-31, polynucleotide and expression vectors encoding antibodies, methods for their production and use
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
MY191348A (en) Antibodies and derivatives thereof
NZ598770A (en) Monoclonal antibodies
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
EP2186884A3 (en) HCV-anti-core monoclonal antibody
MY155144A (en) NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
NZ583894A (en) Antibodies that bind to a non atp binding p2x7 receptor
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet

Legal Events

Date Code Title Description
FG Grant or registration